Meyer H, Hartmann H, Steinbach G, Schulz W, Günther H, Kiupel H, Koch H, Linde K
Arch Exp Veterinarmed. 1977;31(2):277-88.
The oral vaccine, prepared on the basis of streptomycindependent mutants for administration to control S.-dublin infection, was clinically tested on 2,210 calves of 22 herds. The experimentally obtained findings regarding good tolerance and sufficient effectiveness of oral live vaccines were thus confirmed under field conditions. Good effectiveness of the oral vaccine was reflected in the recorded decline of clinical salmonellosis cases and of calf losses due to salmonellosis, and it was established also by bacteriological identification of S. dublin in faecal samples, histological sections, and material obtained from emergency slaughter carcasses. A comparison between this oral vaccine and "Mellavax" an imported vaccine for subcutaneous adminstration with good effectiveness, revealed superiority of the oral vaccine by almost all criteria of action. Particular importance was attributed to the significant reduction of the number of Salmonella-excreting animals (faeces) following oral immunisation. The oral vaccine against Dublin salmonellosis of calf was disembargoed for production in 1975 under the name of "Salmonella-dublin Live Vaccine Dessau".
基于链霉素依赖型突变体制备的用于控制都柏林沙门氏菌感染的口服疫苗,在22个牛群的2210头犊牛身上进行了临床试验。因此,在田间条件下证实了实验得出的关于口服活疫苗耐受性良好和有效性充分的结果。口服疫苗的良好效果体现在记录的临床沙门氏菌病病例减少以及因沙门氏菌病导致的犊牛损失减少,并且通过对粪便样本、组织切片以及紧急屠宰尸体材料中的都柏林沙门氏菌进行细菌学鉴定也得以证实。将这种口服疫苗与具有良好效果的进口皮下注射疫苗“Mellavax”进行比较,结果显示口服疫苗在几乎所有作用标准方面都具有优势。特别重要的是,口服免疫后排出沙门氏菌的动物(粪便)数量显著减少。预防犊牛都柏林沙门氏菌病的口服疫苗于1975年解禁投入生产,商品名为“都柏林沙门氏菌活疫苗德绍”。